BibTex format
@article{Vassileva:2026:10.1016/j.rmed.2026.109067,
author = {Vassileva, SM and Khamas, SS and Dyhre-Petersen, N and Principe, S and Vijverberg, SJ and Hilvering, B and Weersink, EJM and Bricaud, AL and Bari, EJ and Sverrild, A and Shah, PA and Singapuri, A and Sereno, M and Ntotsis, K and Clarke, GW and Azim, A and Chaudhuri, R and Fowler, SJ and Schleich, F and Siddiqui, S and Andersson, LI and Kerr, M and Crone, E and Wilde, MJ and Lozano-Rojas, DF and Quann, N and Bonta, PI and Annema, JT and Brightling, C and Dahlén, S-E and Porsbjerg, C and Maitland-Van, der Zee AH and Brinkman, P},
doi = {10.1016/j.rmed.2026.109067},
journal = {Respir Med},
title = {The impact of benralizumab and dupilumab on exhaled volatile organic compound profiles of severe asthma patients - a preliminary analysis.},
url = {http://dx.doi.org/10.1016/j.rmed.2026.109067},
volume = {262},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Volatile organic compounds (VOCs) in exhaled breath reflect biological processes in the lungs. Exploring VOC profiles in severe asthma patients starting biologics may reveal treatment-related biological changes over time. This study aimed to assess the performance and feasibility of applying a sparse partial least squares-discriminant analysis (sPLS-DA) analytical approach in detecting longitudinal changes in exhaled VOCs of patients with severe asthma initiating biologic treatment. Exhaled breath was collected in the 3TR-ABC study, a multicenter observational prospective cohort study, at baseline and 4 months after starting biologics (benralizumab or dupilumab). VOCs were trapped on thermal desorption tubes and analyzed by gas chromatography-mass spectrometry. Paired sPLS-DA was used to distinguish baseline from post-treatment VOC profiles, and Kendall rank correlation assessed associations with clinical parameters at baseline. Data from two sites (Amsterdam and Copenhagen) were available of 25 severe asthma patients. The sPLS-DA resulted in a model containing five VOCs (methyl isobutyl ketone, 2-ethyl-1-hexanol, 5-methyl octadecane, 2-methylundecane and 1,1'-oxybis(decane)) with an area under the receiver operating characteristic curve of 0.89 (95% confidence interval: 0.79-0.99) for distinguishing baseline and 4 months post treatment. At baseline, a positive correlation was observed between 2-ethyl-1-hexanol and asthma control (Asthma Control Questionnaire); τ=0.40, p<0.01. A negative correlation was found between 1,1'- oxybis(decane) and blood eosinophil counts (τ=-0.30, p=0.04). Based on our results, the proposed analytical approach appears feasible for analyzing longitudinal data in patients with severe asthma initiating biologics. Further validation in larger cohorts is warranted to confirm robustness and generalizability.
AU - Vassileva,SM
AU - Khamas,SS
AU - Dyhre-Petersen,N
AU - Principe,S
AU - Vijverberg,SJ
AU - Hilvering,B
AU - Weersink,EJM
AU - Bricaud,AL
AU - Bari,EJ
AU - Sverrild,A
AU - Shah,PA
AU - Singapuri,A
AU - Sereno,M
AU - Ntotsis,K
AU - Clarke,GW
AU - Azim,A
AU - Chaudhuri,R
AU - Fowler,SJ
AU - Schleich,F
AU - Siddiqui,S
AU - Andersson,LI
AU - Kerr,M
AU - Crone,E
AU - Wilde,MJ
AU - Lozano-Rojas,DF
AU - Quann,N
AU - Bonta,PI
AU - Annema,JT
AU - Brightling,C
AU - Dahlén,S-E
AU - Porsbjerg,C
AU - Maitland-Van,der Zee AH
AU - Brinkman,P
DO - 10.1016/j.rmed.2026.109067
PY - 2026///
TI - The impact of benralizumab and dupilumab on exhaled volatile organic compound profiles of severe asthma patients - a preliminary analysis.
T2 - Respir Med
UR - http://dx.doi.org/10.1016/j.rmed.2026.109067
UR - https://www.ncbi.nlm.nih.gov/pubmed/42556744
VL - 262
ER -